Given the striking upregulation of MAFB in response to MYB suppression, we reasoned that ectopic expression of MAFB could phenocopy the consequences of MYB inhibition and, as such, could represent a novel therapeutic avenue for the treatment of MLL-rearranged leukaemias. Here, KMT2A is linked to leukemia.